ID   TAOK1_RAT               Reviewed;        1001 AA.
AC   O88664;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   24-JUL-2024, entry version 155.
DE   RecName: Full=Serine/threonine-protein kinase TAO1;
DE            EC=2.7.11.1;
DE   AltName: Full=Thousand and one amino acid protein 1;
GN   Name=Taok1; Synonyms=Tao1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, INTERACTION WITH MKK3,
RP   AUTOPHOSPHORYLATION, AND MUTAGENESIS OF ASP-169.
RX   PubMed=9786855; DOI=10.1074/jbc.273.44.28625;
RA   Hutchison M., Berman K.S., Cobb M.H.;
RT   "Isolation of TAO1, a protein kinase that activates MEKs in stress-
RT   activated protein kinase cascades.";
RL   J. Biol. Chem. 273:28625-28632(1998).
RN   [2]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH MARK2.
RX   PubMed=14517247; DOI=10.1093/emboj/cdg447;
RA   Timm T., Li X.Y., Biernat J., Jiao J., Mandelkow E., Vandekerckhove J.,
RA   Mandelkow E.M.;
RT   "MARKK, a Ste20-like kinase, activates the polarity-inducing kinase
RT   MARK/PAR-1.";
RL   EMBO J. 22:5090-5101(2003).
RN   [3]
RP   FUNCTION.
RX   PubMed=17047359; DOI=10.1159/000095258;
RA   Timm T., Matenia D., Li X.Y., Griesshaber B., Mandelkow E.M.;
RT   "Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and
RT   pathological phosphorylation.";
RL   Neurodegener. Dis. 3:207-217(2006).
RN   [4]
RP   INTERACTION WITH TESK1 AND SPRED1, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   LYS-57.
RX   PubMed=18216281; DOI=10.1091/mbc.e07-07-0730;
RA   Johne C., Matenia D., Li X.Y., Timm T., Balusamy K., Mandelkow E.M.;
RT   "Spred1 and TESK1--two new interaction partners of the kinase MARKK/TAO1
RT   that link the microtubule and actin cytoskeleton.";
RL   Mol. Biol. Cell 19:1391-1403(2008).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various processes
CC       such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response
CC       and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6
CC       and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK
CC       cascade by mediating phosphorylation and subsequent activation of the
CC       upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled
CC       receptor signaling to p38/MAPK14. In response to DNA damage, involved
CC       in the G2/M transition DNA damage checkpoint by activating the
CC       p38/MAPK14 stress-activated MAPK cascade, probably by mediating
CC       phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of
CC       cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading
CC       to activate MARK2 kinase activity and subsequent phosphorylation and
CC       detachment of MAPT/TAU from microtubules. Also acts as a regulator of
CC       apoptosis: regulates apoptotic morphological changes, including cell
CC       contraction, membrane blebbing and apoptotic bodies formation via
CC       activation of the MAPK8/JNK cascade. During fetal development, it plays
CC       an essential role in the regulation of neuronal differentiation and
CC       migration to the cortical plate (By similarity).
CC       {ECO:0000250|UniProtKB:Q5F2E8, ECO:0000269|PubMed:14517247,
CC       ECO:0000269|PubMed:17047359}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:14517247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:14517247};
CC   -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is
CC       inhibited by SPRED1. {ECO:0000269|PubMed:18216281}.
CC   -!- SUBUNIT: Self-associates. Interacts with MAP2K3. Interacts with SPRED1
CC       (PubMed:18216281). Interacts with TESK1; the interaction inhibits TAOK1
CC       kinase activity (PubMed:18216281). Interacts with MAP3K7 (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:14517247,
CC       ECO:0000269|PubMed:18216281, ECO:0000269|PubMed:9786855}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- PTM: Proteolytically processed by caspase-3 (CASP3). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated (By similarity). Phosphorylated by ATM in
CC       response to DNA damage. Phosphorylated by LRRK2 (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF084205; AAC71014.1; -; mRNA.
DR   PIR; T17365; T17365.
DR   RefSeq; NP_775449.1; NM_173327.1.
DR   AlphaFoldDB; O88664; -.
DR   SMR; O88664; -.
DR   BioGRID; 251966; 1.
DR   STRING; 10116.ENSRNOP00000021368; -.
DR   iPTMnet; O88664; -.
DR   PhosphoSitePlus; O88664; -.
DR   jPOST; O88664; -.
DR   PaxDb; 10116-ENSRNOP00000021368; -.
DR   GeneID; 286993; -.
DR   KEGG; rno:286993; -.
DR   AGR; RGD:708455; -.
DR   CTD; 57551; -.
DR   RGD; 708455; Taok1.
DR   eggNOG; KOG0577; Eukaryota.
DR   InParanoid; O88664; -.
DR   OrthoDB; 2879376at2759; -.
DR   PhylomeDB; O88664; -.
DR   Reactome; R-RNO-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-RNO-2467813; Separation of Sister Chromatids.
DR   Reactome; R-RNO-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-RNO-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-RNO-68877; Mitotic Prometaphase.
DR   Reactome; R-RNO-9648025; EML4 and NUDC in mitotic spindle formation.
DR   PRO; PR:O88664; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0015630; C:microtubule cytoskeleton; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0043014; F:alpha-tubulin binding; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0048487; F:beta-tubulin binding; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; ISO:RGD.
DR   GO; GO:0031489; F:myosin V binding; IPI:RGD.
DR   GO; GO:0030295; F:protein kinase activator activity; IMP:RGD.
DR   GO; GO:0004672; F:protein kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:ARUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; ISS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0097194; P:execution phase of apoptosis; ISS:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISO:RGD.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; ISS:UniProtKB.
DR   GO; GO:0007026; P:negative regulation of microtubule depolymerization; ISO:RGD.
DR   GO; GO:0070050; P:neuron cellular homeostasis; ISO:RGD.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISS:UniProtKB.
DR   GO; GO:1901985; P:positive regulation of protein acetylation; ISO:RGD.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:ARUK-UCL.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IMP:ARUK-UCL.
DR   CDD; cd06635; STKc_TAO1; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR051234; TAO_STE20_kinase.
DR   PANTHER; PTHR47167; SERINE/THREONINE-PROTEIN KINASE TAO1-LIKE PROTEIN; 1.
DR   PANTHER; PTHR47167:SF8; SERINE_THREONINE-PROTEIN KINASE TAO1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; ATP-binding; Coiled coil; Cytoplasm; DNA damage; DNA repair;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..1001
FT                   /note="Serine/threonine-protein kinase TAO1"
FT                   /id="PRO_0000086730"
FT   DOMAIN          28..281
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          324..380
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          404..431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          567..587
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          905..1001
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          458..651
FT                   /evidence="ECO:0000255"
FT   COILED          754..877
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        340..374
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        958..1001
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         34..42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         57
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L7X3"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L7X3"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L7X3"
FT   MOD_RES         669
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L7X3"
FT   MOD_RES         965
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L7X3"
FT   MUTAGEN         57
FT                   /note="K->A: Loss of serine/threonine-protein kinase
FT                   without affecting interaction with SPRED1."
FT                   /evidence="ECO:0000269|PubMed:18216281"
FT   MUTAGEN         169
FT                   /note="D->A: No kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9786855"
SQ   SEQUENCE   1001 AA;  115952 MW;  85511B62DBD62FCC CRC64;
     MPSTNRAGSL KDPEIAELFF KEDPEKLFTD LREIGHGSFG AVYFARDVRT NEVVAIKKMS
     YSGKQSTEKW QDIIKEVKFL QRIKHPNSIE YKGCYLREHT AWLVMEYCLG SASDLLEVHK
     KPLQEVEIAA ITHGALQGLA YLHSHTMIHR DIKAGNILLT EPGQVKLADF GSASMASPAN
     SFVGTPYWMA PEVILAMDEG QYDGKVDVWS LGITCIELAE RKPPLFNMNA MSALYHIAQN
     ESPTLQSNEW SDYFRNFVDS CLQKIPQDRP TSEELLKHMF VLRERPETVL IDLIQRTKDA
     VRELDNLQYR KMKKLLFQEA HNGPAVEAQE EEEEQDHGGG RTGTVNSVGS NQSIPSMSIS
     ASSQSSSVNS LPDASDDKSE LDMMEGDHTV MSNSSVIHLK PEEENYQEEG DPRTRASAPQ
     SPPQVSRHKS HYRNREHFAT IRTASLVTRQ MQEHEQDSEL REQMSGYKRM RRQHQKQLMT
     LENKLKAEMD EHRLRLDKDL ETQRNNFAAE MEKLIKKHQA SMEKEAKVMA NEEKKFQQHI
     QAQQKKELNS FLESQKREYK LRKEQLKEEL NENQSTPKKE KQEWLSKQKE NIQHFQAEEE
     ANLLRRQRQY LELECRRFKR RMLLGRHNLE QDLVREELNK RQTQKDLEHA MLLRQHESMQ
     ELEFRHLNTI QKMRCELIRL QHQTELTNQL EYNKRREREL RRKHVMEVRQ QPKSLKSKEL
     QIKKQFQDTC KIQTRQYKAL RNHLLETTPK SEHKAVLKRL KEEQTRKLAI LAEQYDHSIN
     EMLSTQALRL DEAQEAECQV LKMQLQQELE LLNAYQSKIK MQAEAQHDRE LRELEQRVSL
     RRALLEQKIE EEMLALQNER TERIRSLLER QAREIEAFDS ESMRLGFSNM VLSNLSPEAF
     SHSYPGASSW SHNPTGGSGP HWGHPMGGTP QAWGHPMQGG PQPWGHPSGP MQGVPRGSSI
     GVRNSPQALR RTASGGRTEQ GMSRSTSVTS QISNGSHMSY T
//
